Moneycontrol
Get App
Last Updated : Dec 31, 2018 12:13 PM IST | Source: Moneycontrol.com

Cadila Healthcare may test Rs 435: Anand Rathi

We expect 11 percent and 17 percent CAGRs over FY18-20 in revenue & earnings respectively.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare is one of the top three in gynaecology, respiratory, pain management, CVS and dermatology.

We believe a pick-up in market share of gToprol, launches and the launched Asacol HD (own version) would help maintain Cadila’s margins

and earnings ahead. On the high base, we expect 8 percent and 9 percent CAGRs over FY18-21 in revenue and earnings respectively.

The company expects 40-50 launches annually and is focusing on vaccines and biologics – which could be future growth drivers.

It has strong ANDA pipeline in the US, with 144 filings awaiting approval of which 60+ are Para IV. It launched 20 products in the year,

including g Lialda and gTamiflu and received 77 approvals in FY18, bringing cumulative filings/approvals to 330/186.

The company has recently announced it is considering fund raising proposals of up to Rs 10,000 Cr via QIP & up to Rs 5,000 cr via FCCBs.

We expect 11 percent and 17 percent CAGRs over FY18-20 in revenue & earnings respectively, our target price is based on 21x FY20e EPS of23.30.
First Published on Dec 31, 2018 12:13 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant